Concurrent treatment may lead to temporary impairment of consciousness.
Source: NLP:deferoxamine mesylate
2 interactions on record
Concurrent treatment may lead to temporary impairment of consciousness.
Source: NLP:deferoxamine mesylate
QT interval prolonging drug. Coadministration with VANFLYTA may further increase incidence of QT prolongation. More frequent ECG monitoring recommended.
Source: NLP:quizartinib